Review of the Business.
Overview of the company’s services
Dr Julian Medical Group (“DJMG”) is a healthcare technology and CQC-registered clinical services company. The Company provides digital healthcare infrastructure and clinical services designed to connect healthcare organisations, clinicians and patients, improve access to care and support better clinical outcomes.
DJMG provides Software as a Service (“SaaS”) solution to healthcare organisations alongside clinical services delivered remotely and in person. The Company’s clinical services are delivered in accordance with relevant National Institute for Health and Care Excellence (“NICE”) guidance and applicable clinical and regulatory standards.
DJMG’s proprietary JMIS (Joined-up Mental Health Information System) platform provides digital infrastructure for the management and delivery of healthcare pathways. The platform can be deployed as a standalone technology solution, integrated alongside existing systems, combined with DJMG’s clinical workforce, or used as part of an end-to-end healthcare delivery model.
Operational highlights
The 2025/26 financial year saw an improvement in the Company’s financial performance, supported by disciplined cost management, operational efficiencies and continued development of the Company’s technology and clinical service propositions.
During the year, DJMG expanded its clinical capabilities across children and young people’s services, eating disorders, secondary care and neurodiversity, while securing new contracts and partnerships across the NHS and wider healthcare sector.
The Company also continued to expand its SaaS proposition and the capabilities of JMIS, including its Resource Library Builder and digital front door functionality. These capabilities are designed to support improved access to healthcare services, personalised digital support, population health initiatives and preventative models of care.
Strategic objectives and achievements
The disciplined approach adopted by the executive team during 2025/26 supported an improvement in the Company’s financial position while allowing continued investment in its technology and clinical capabilities.
Key Objectives
The Company’s key objectives during the year included:
expanding its ADHD and neurodiversity offering to support pre-screening, assessment, diagnosis, treatment and ongoing care pathways.
further developing an integrated proposition combining SaaS technology, digital resources and clinical service provision.
enhancing the JMIS platform, including video functionality, digital pathway management, resource delivery and administrative automation; and
maintaining a focus on operational efficiency while continuing to deliver high-quality clinical care.
Clinical performance remained strong during the year, with key clinical outcomes continuing to exceed relevant NHS targets and patient feedback remaining consistently positive.
The Company continued to secure extensions and expansions of existing customer relationships, establish new partnerships with NHS providers and Integrated Care Boards, and win new contracts through competitive procurement exercises.
DJMG also successfully secured three digital innovation grants through the Health Innovation Network, supporting the continued development and deployment of its digital healthcare capabilities.
Market overview
Mental health, neurodiversity and wider population health remain significant areas of focus for the NHS, private healthcare providers and insurers. Commissioners and providers continue to seek approaches that support earlier intervention, preventative care, improved access, workforce efficiency and the effective use of digital healthcare infrastructure.
In response to these developments, DJMG has continued to develop JMIS as interoperable healthcare infrastructure capable of supporting multiple services and pathways. This includes API capabilities designed to facilitate integration with partner applications and existing healthcare systems and support the secure and efficient flow of information across healthcare pathways.
The Company has also continued to develop complementary digital tools supporting self-referral, digital access, personalised resources, pathway management, outcome measurement and population-level reporting.
Future outlook
The Company enters the next financial period with an expanded clinical and technology proposition and a growing number of opportunities across NHS, public sector and private healthcare markets. DJMG intends to increase its participation in competitive procurement opportunities, deepen existing strategic partnerships and continue developing its SaaS and integrated technology and clinical service propositions.
The Company will also continue to explore opportunities to deploy its technology infrastructure across broader healthcare pathways and regional models of care, while expanding its specialist clinical capabilities.
The executive team remains focused on sustainable growth, operational efficiency, continued product development and maintaining high standards of clinical quality and governance.
Conclusion
The Company has demonstrated resilience and adaptability through a period of significant change within the healthcare market. DJMG has strengthened its financial position, expanded its clinical capabilities, continued to develop its proprietary technology and established new customer and strategic relationships.
With an experienced executive team and an increasingly integrated technology and clinical service offering, the Company remains committed to its mission of improving access, connectivity and outcomes across healthcare.